70% of Genetic Rare Diseases Start in Childhood
70% of genetic rare diseases start in childhood. Many rare diseases may result in the premature death of infants or can be fatal in early childhood. 80% of children with…
ACHONDROPLASIA
-
-
Kickoff to Rare Disease Month
Did you know that rare diseases affect an estimated 350 million people worldwide? According to the National Organization for Rare Disorders, achondroplasia, the most common form of dwarfism, is considered…
-
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated…
-
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in Europe SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today…
-
Vosoritide in Europe: will payers cover BioMarin’s dwarfism drug?
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for dwarfism. Need to know Vosoritide is…
-
BioMarin gears up for two ‘transformational’ launches, Voxzogo and Roctavian: CEO
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two next-gen medicines. And no wonder: Those drugs, Voxogo and Roctavian, could completely…
